# PYRIMIDINE NUCLEOSIDE PHOSPHORYLASES IN CHEMOTHERAPY

> **NIH NIH R01** · BROWN UNIVERSITY · 1991 · $142,347

## Abstract

The objectives of this grant proposal are:

1. Chemical synthesis of analogs and derivatives of BAU
(5-benzylacyclouridine) and BBAU (5-benzyloxybenzylacyclouridine), potent
inhibitors of uridine phosphorylase and potentiators of the anti-tumor
action of FUdR, designed to improve facility of clinical use, to produce
new anti-tumor drugs and pro-drugs, and to explore further their biological
properties.

2. Biological testing of these new agents as inhibitors of uridine
phosphorylase and, where indicated, thymidine phosphorylase, as transport
inhibitors, anti-tumor agents and potentiators both in vitro and in vivo,
and as tools for obtaining new biochemical knowledge related to nucleic
acid metabolism.

These studies will be performed in collaboration with colleagues in the
Roger Williams Cancer Center.

## Key facts

- **NIH application ID:** 3178386
- **Project number:** 5R01CA039427-05
- **Recipient organization:** BROWN UNIVERSITY
- **SAM.gov UEI:** E3FDXZ6TBHW3
- **Principal Investigator:** SHIH HSI CHU
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1991
- **Award amount:** $142,347
- **Award type:** 5
- **Project period:** 1985-09-01 → 1992-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3178386

## Citation

> US National Institutes of Health, RePORTER application 3178386, PYRIMIDINE NUCLEOSIDE PHOSPHORYLASES IN CHEMOTHERAPY (5R01CA039427-05). Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/grant/nih/3178386. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*